Your activity: 144 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Overview of pharmacotherapy for insomnia in adults

Overview of pharmacotherapy for insomnia in adults
CBT-I: cognitive behavioral therapy for insomnia; DORA: dual orexin receptor antagonist; OTC: over the counter; BZRA: benzodiazepine receptor agonist; IR: immediate release; ER: extended release; MOTN: middle of the night.
* When used, medications should be part of a holistic approach that includes healthy sleep habits, adequate opportunity for sleep, treatment of relevant comorbidities, and CBT-I when appropriate and available. Treatment selection is individualized based on the nature of the insomnia symptoms, past treatment responses, medication availability and cost, side effects, comorbidities, and patient preferences.
¶ BZRAs include benzodiazepines and nonbenzodiazepine BZRAs such as zolpidem. Common reasons to avoid may include older age, history of substance use disorder, or patient preference.
Δ Off-label prescribing of sedating medications for insomnia should be considered primarily for patients who do not have an adequate therapeutic response to first-line medications with regulatory approval for insomnia, when a different mechanism of action is desired, or when there is a specific reason to avoid BZRAs. Doses of such medications for insomnia purposes are generally subtherapeutic for the relevant comorbidity.
Not recommended for chronic use. Avoid use in older adults.
Graphic 129521 Version 2.0